(Q38252851)

English

Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).

scientific article published on 16 September 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). (English)

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

0 references

placebo-controlled trial

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Michael J. Morris

11

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

Lars Edenbrandt

7

object named as

Lars Edenbrandt

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

author name string

Andrew J Armstrong

1

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

Reza Kaboteh

2

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

Michael A Carducci

3

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

Jan-Erik Damber

4

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

Walter M Stadler

5

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

Mats Hansen

6

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

Göran Forsberg

8

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

Örjan Nordle

9

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

Roberto Pili

10

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

publication date

16 September 2014

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

Urologic Oncology

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

32

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

8

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

1308-1316

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

Quality of planar whole-body bone scan interpretations--a nationwide survey

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan index

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Alpha emitter radium-223 and survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Bone Scan Index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Developing imaging strategies for castration resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Improved classifications of planar whole-body bone scans using a computer-assisted diagnosis system: a multicenter, multiple-reader, multiple-case study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

S100A9 interaction with TLR4 promotes tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2014.08.006

7 January 2021

Quantitative bone metastases analysis based on image segmentation.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25240761

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.UROLONC.2014.08.006

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

1 July 2019

http://europepmc.org/abstract/PMC/6341998

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38252851&oldid=1877338580"